The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)

British Journal of Clinical Pharmacology

Volumn 44, Issue 6, 1997, Pages 595-599

  Peck, Richard W ^a   Seaber, Emma J ^a   Dixon, Ruth ^a,b   Gillotin, Catherine G ^a,c   Weatherley, Barry C ^a   Layton, Gary ^a,d   Posner, John ^a,e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c GlaxoWellcome   (France)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e Bios Ltd   (United Kingdom)

Author keywords

Interaction; Migraine; Propranolol; Zolmitriptan

Indexed keywords

ANTIMIGRAINE AGENT; DRUG METABOLITE; PLACEBO; PROPRANOLOL; ZOLMITRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0030695886     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00632.x     Document Type: Article

References (16)

1. 1D receptor agonist 311C90. New Advances Headache Res 1994; 4: 3-4.
2. Ferrari MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurology 1996; 36 (Suppl 2): 4-7.
3. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996; 41: 141-147.
4. Seaber E, On N, Dixon RM, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997; 43: 579-587.
5. Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolnntriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 1997; 43: 273-281.
6. Welch KMA. Drug therapy of migraine. New Engl J Med 1993; 329: 1476-1483.
7. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications (3rd edition). Baltimore: Lea & Febiger, 1995.
8. Koch GG. The use of non-parametric methods in the statistical analysis of the two period crossover design. Biometrics 1972: 82: 577-584.
9. Stinson JC, Pears JS, Williams AJ, Campbell RW. Use of 24 h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers. Br J Clin Pharmacol 1995; 39: 651-656.
10. Soons PA, DeBoer A, Cohen AF, Breimer D. The assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green. Br J Clin Pharmacol 1991; 32: 697-704.
11. Rowland K, Yeo WW, Ellis SW, et al. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxypropranolol. Br J Clin Pharmacol 1994; 38: 9-14.
12. Bax NDS, Tucker GT, Lennard MS, Woods HF. The impairment of lignocaine clearance by propranolol - major contribution from enzyme inhibition. Br J Clin Pharmacol 1985; 19: 597-603.
13. Conrad KA, Nyman DW. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther 1980; 28: 463-467.
14. Walle T, Walle K, Cowart D, Conradi E. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989; 46: 257-263.
15. Dixon CM, Park GR, Tarbit MH. Characterisation of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 1994; 47: 1253-1257.
16. Walle T, Walle UK, Olanoff LS. Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos 1985; 13: 204-209.